Intangible asset

Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update

Retrieved on: 
Wednesday, November 8, 2023
FDA, Research, Yoy, PDUFA, Catalysis, Intangibles, Anticipation, GAAP, Acquisition, Orange Book, Development, Vamorolone, Bank statement, PMDA, Growth, Amifampridine, COVID-19, Duchenne muscular dystrophy, Webcast, Intangible asset, Lambert–Eaton myasthenic syndrome, IPR, NDA, Epilepsy, Accounting, Administration, Cash, YTD, Bank, Pharmaceutical industry, Beauty salon, Video game, Cryptocurrency

These non-GAAP financial measures are intended to enhance an overall understanding of Catalyst's current financial performance.

Key Points: 
  • These non-GAAP financial measures are intended to enhance an overall understanding of Catalyst's current financial performance.
  • Non-GAAP financial measures should not be considered in isolation or as a substitute for comparable GAAP accounting.
  • Intangible assets acquired after the third quarter of 2022 relate to the FYCOMPA rights acquired in the first quarter of 2023.
  • The Company will host a conference call and webcast on Thursday, November 9, 2023, at 8:30 AM ET to discuss the financial results and provide a business update.

RM plc: Sale of IPv4 addresses

Retrieved on: 
Tuesday, October 17, 2023
MAR, IP, School, European Union (Withdrawal) Act 2018, RM, Disclosure, ICT, RM Education, Listing Rules, Intangible asset, Education, Internet Protocol version 4, Growth, LSE, University, Software, Learning, Sales, Sale, Risk management, Tutoring, EU

RM plc, a leading international supplier of technology and resources to the education sector (LSE: RM) (“RM”, the “Company”), today announces that it has agreed to sell an additional portion of its Internet Protocol v4 (“IPv4”) addresses (“the Sale”) to Hilco Streambank (“Hilco”) for a total consideration of $2.2m in cash.

Key Points: 
  • RM plc, a leading international supplier of technology and resources to the education sector (LSE: RM) (“RM”, the “Company”), today announces that it has agreed to sell an additional portion of its Internet Protocol v4 (“IPv4”) addresses (“the Sale”) to Hilco Streambank (“Hilco”) for a total consideration of $2.2m in cash.
  • These sales have been classified as other income in line with the treatment of the sale of Intangible Assets.
  • The Sale, when aggregated with the previous sale of $10.2m of IP addresses, as announced on 28 December 2022, will constitute a Class 2 transaction under the Listing Rules.
  • The Company retains the rights over a further c.213,000 IPv4 addresses, which will support growth in RM Technology’s connectivity business.

Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, August 9, 2023
Amifampridine, Epilepsy, Vamorolone, Cash, Duchenne muscular dystrophy, BioMarin Pharmaceutical, Bank statement, Medicines and Healthcare products Regulatory Agency, COVID-19, Intangible asset, NDA, GAAP, Duchenne, Accounting, Medication, Pharmaceuticals and Medical Devices Agency, Development, State Administrative Expenses, Shanda, Acquisition, Lambert–Eaton myasthenic syndrome, Administration, PMDA, PDUFA, Webcast, Intangibles, Yoy, ESG, Research, Catalysis, Bank, Beauty salon, Video game, Pharmaceutical industry, Cryptocurrency

CORAL GABLES, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “the Company”) (Nasdaq: CPRX) today reported financial results for the second quarter of 2023 and provided a corporate update.

Key Points: 
  • Research and Development Expenses: Research and development expenses were $4.0 million in both the second quarter of 2023 and 2022.
  • Selling, General, and Administrative Expenses: Selling, general, and administrative expenses for the second quarter of 2023 were $28.4 million, compared to $12.9 million in the second quarter of 2022.
  • Amortization of Intangible Assets: Amortization of intangible assets was $8.5 million in the second quarter of 2023, compared to $0 million in the second quarter of 2022.
  • Operating Income: Operating income for the second quarter of 2023 was $46.7 million, compared to $28.6 million in the second quarter of 2022, representing an increase of 63.5% year-over-year.

Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year

Retrieved on: 
Wednesday, May 10, 2023
LEMS, Anticipation, Bank statement, Medicines and Healthcare products Regulatory Agency, New Drug Application, COVID-19, Intangible asset, NDA, GAAP, Accounting, Medication, Development, Acquisition, Lambert–Eaton myasthenic syndrome, Administration, PMDA, Intangibles, Webcast, Biophysical environment, Depreciation, ESG, Yoy, Research, Amifampridine, Catalysis, Pharmaceuticals and Medical Devices Agency, Bank, Video game, Beauty salon, Reinsurance, Cryptocurrency

Achieved Q1 2023 FIRDAPSE® net product revenue of $57.5 Million, representing a substantial 34% YoY increase.

Key Points: 
  • Achieved Q1 2023 FIRDAPSE® net product revenue of $57.5 Million, representing a substantial 34% YoY increase.
  • Research and Development Expenses: Research and development expenses in the first quarter of 2023 were $3.6 Million, compared to $3.4 Million in the first quarter of 2022.
  • Amortization of Intangible Assets: Amortization of intangible assets was $6.5 Million in the first quarter of 2023, compared to $0.00 in the first quarter of 2022.
  • 2023 Financial Guidance: The Company forecasts full-year 2023 total revenues, including FYCOMPA®, to be between $375 Million and $385 Million, representing a 75% - 80% increase in total revenues compared to 2022.

Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2023

Retrieved on: 
Tuesday, April 25, 2023
Risk factor, Marketing, IIA, Calendar, Intangible asset, CAD, Ageing, GP, Woman, G&A, EBT, Absorption, NOE, Government, AUD, OE, Hospital, EBITDA, Acquisition, Investment, NI, Patient, FX, Clotrimazole, NOI, Depreciation, EPS, R, OEM, OUS, GPM, GBP, OI, CSI, Renewable energy, Beauty salon, Pharmaceutical industry, Clothing, Bookkeeping, Holding company, Cryptocurrency, USD, EUR

Consolidated G&A expenses were $2,873 (22.9% of sales) in 1Q 2023 compared to $2,551 (20.7% of sales) in 1Q 2022.

Key Points: 
  • Consolidated G&A expenses were $2,873 (22.9% of sales) in 1Q 2023 compared to $2,551 (20.7% of sales) in 1Q 2022.
  • The EBT of Utah Medical Products, Inc. in the U.S. was $2,562 in 1Q 2023 compared to $2,916 in 1Q 2022.
  • The EBT of Utah Medical Products, Ltd (Ireland) was EUR 1,962 in 1Q 2023 compared to EUR 1,806 in 1Q 2022.
  • The 1Q 2023 EBT of Utah Medical Products Canada, Inc. was CAD 158 in 1Q 2023 compared to CAD 154 in 1Q 2022.

High Tide Announces Management Change and Corrects Disclosure

Retrieved on: 
Wednesday, February 15, 2023
Bank statement, Control, CMA, Process, Supply chain, EDGAR, SEDAR, Disclosure, News, University, CPA, Adviser, University of Alberta, AB, High Tide, FSE, Master, Oil, Intangible asset, Amend, Certification, Supply, Typesetting, Audit, Mining

To fill the vacancy following Mr. Kanji's departure, the Company is pleased to announce the appointment of Sergio Patino as interim Chief Financial Officer, effective February 28, 2023.

Key Points: 
  • To fill the vacancy following Mr. Kanji's departure, the Company is pleased to announce the appointment of Sergio Patino as interim Chief Financial Officer, effective February 28, 2023.
  • Mr. Patino is a Chartered Professional Accountant (CPA, CMA), and has a Master's in business from University of Alberta.
  • He joined High Tide as a Financial Consultant in November of 2022 bringing more than 20 years of global experience across multiple industries.
  • Prior to joining High Tide, he was the America's Chief Financial Officer of a large Mining Construction company.

Sale of IP addresses

Retrieved on: 
Sunday, January 22, 2023
Education, IPv4, Software, Sale, School, IP, Disclosure, RM Education, Growth, Intangible asset, RM, Learning, Listing Rules, LSE, European Union (Withdrawal) Act 2018, ICT, MAR, University, Private investigator, Risk management, EU

The Company retains the rights over a further c.294,000 IPv4 addresses which will support growth in RM’s connectivity business.

Key Points: 
  • The Company retains the rights over a further c.294,000 IPv4 addresses which will support growth in RM’s connectivity business.
  • The IP addresses are classified as intangible assets and were acquired at nil value.
  • The Sale will therefore not affect the Company’s total net assets, other than the addition of the cash proceeds from the Sale which will be used to strengthen the balance sheet.
  • Approximately £4.1m of IP addresses were sold during FY22 (ending on 30 November 2022) which, due to the changing nature of these sales in the period, have been classified as other income for FY22 in line with the treatment of the sale of Intangible Assets.

Danaher Reports Third Quarter 2022 Results

Retrieved on: 
Thursday, October 20, 2022
Time, Biophysical environment, Danaher Corporation, Therapy, Pandemic, Danaher, Vaccine, COVID-19 testing, GAAP, Series A round, Intangible asset, History, Technology, EPS, Venture round, Mergers and acquisitions, Company, Acquisition, Diagnosis, MCPS, Continuous operation, Stock dilution, Nature, FCF, COVID-19, Insurance, Security (finance), Bank, Risk management

This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table.

Key Points: 
  • This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table.
  • In addition, the footnotes above indicate the after-tax amount of each individual adjustment item.
  • Each share of MCPS Series A converted on April 15, 2022 into 6.6632 shares of Danaher's common stock.
  • We believe this presentation provides useful information to investors by helping them understand what the net impact will be on Danaher's earnings per share-related measures once the MCPS convert into Danaher common stock.

IPwe announces a capital and business partnership with ADVASA, a provider of "Earned Wage Access" service

Retrieved on: 
Wednesday, October 12, 2022
Fiat, Growth, Society, B2B, Software as a service, HQ, Web3, Multimedia, Earned Wage Access, Partnership, Artificial intelligence, Technology, IP, Patent, IPW New Zealand Heavyweight Championship, EWA, Intangible asset, Solution, View, Video game, Cryptocurrency, DALLAS

DALLAS, Oct. 12, 2022 /PRNewswire/ -- IPwe, Inc. (HQ: Delaware, CEO: Erich Spangenberg) announces a capital and business partnership with ADVASA Co., Ltd. (HQ: Tokyo, CEO: Asamitsu Kosugi), a provider of "Earned Wage Access" service to accelerate ADVASA's global business development around EWA by leveraging IPwe's powerful intellectual property platform and extensive corporate patent monetization knowledge and experience worldwide.

Key Points: 
  • Accelerating global rollout of Earned Wage Access (EWA) service, solving issues for both workers and employers, and improving wellbeing.
  • Earned Wage Access is already a successful emerging technology globally, with the U.S. EWA market valued at $12 billion in 2021.
  • By partnering with IPwe, ADVASA can transact their EWA portfolio quickly and at a low cost, efficiently allowing companies worldwide to create Earned Wage Access systems.
  • "IPwe utilized ourSmart Intangible Asset Management platform to analyze ADVASA's portfolio, identifying areas of growth to expand ADVASA's global business objectives.

IPwe announces a capital and business partnership with ADVASA, a provider of "Earned Wage Access" service

Retrieved on: 
Wednesday, October 12, 2022
Fiat, Growth, Society, B2B, Software as a service, HQ, Web3, Earned Wage Access, Partnership, Artificial intelligence, Technology, IP, Patent, IPW New Zealand Heavyweight Championship, EWA, Intangible asset, Solution, Video game, Cryptocurrency, DALLAS

DALLAS, Oct. 12, 2022 /PRNewswire/ --  IPwe, Inc. (HQ: Delaware, CEO: Erich Spangenberg) announces a capital and business partnership with ADVASA Co., Ltd. (HQ: Tokyo, CEO: Asamitsu Kosugi), a provider of "Earned Wage Access" service to accelerate ADVASA's global business development around EWA by leveraging IPwe's powerful intellectual property platform and extensive corporate patent monetization knowledge and experience worldwide.

Key Points: 
  • Accelerating global rollout of Earned Wage Access (EWA) service, solving issues for both workers and employers, and improving wellbeing.
  • Earned Wage Access is already a successful emerging technology globally, with the U.S. EWA market valued at $12 billion in 2021.
  • By partnering with IPwe, ADVASA can transact their EWA portfolio quickly and at a low cost, efficiently allowing companies worldwide to create Earned Wage Access systems.
  • "IPwe utilized ourSmart Intangible Asset Management platform to analyze ADVASA's portfolio, identifying areas of growth to expand ADVASA's global business objectives.